摘要:
Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要:
The present invention relates to the use of compounds of Formula (I) for the treatment of epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, or movement disorders, and to provide neuroprotection.
摘要:
The claimed invention provides a novel method of preparing 6-O-methyl erythromycin A. The process comprises the steps of reducing the 9-keto group of erythromycin A to form a 9-hydroxy erythromycin A, protecting the 9-, 2'-, and/or 4'-hydroxyl groups of erythromycin A, selectively methylating the 6-position of the 9-hydroxy erythromycin A derivative, deprotecting the hydroxyl groups and oxidizing the 9-hydroxyl to afford 6-O-methyl erythromycin A.
摘要:
The disclosed invention relates to novel 3'-N-O, 9-O-oxime protected, 6-O-alkyl erythromycin derivatives of formula (I), a process of preparing the same. The invention also relates to a process of preparing 6-O-alkyl erythromycin A by eliminating the 3'-N-oxide group and 9-O-oxime protecting groups and optionally deprotecting the hydroxy groups at the 2'- and 4''- positions under suitable reaction conditions.
摘要:
A method for the separation of gibberellins from mixtures thereof by selective silylation or desilylation, as well as substantially pure gibberellins prepared thereby. For example, to a solution of a mixture of GA4 and GA7 in DMF was added imidazole. After imidazole was completely dissolved, butyldimethylsilyl chloride was added. After two days of stirring, acetic acid was added which precipitated a white solid (silyl ether of GA7). After filtration GA4 was recovered from the filtrate. Desilylation of the silyl ether of GA7 yielded GA7.
摘要:
A process for preparing a compound of structure (I), where A is oxygen and sulfur and R1 is selected from the group consisting of hydrogen, halogen, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, and trifluoromethyl, and R2 is alkyl of one to four carbon atoms, comprising coupling a compound of formula (II), where X is bromine or iodine, with an N-hydroxyurea compound of formula (III), in the presence of a palladium catalyst. The compounds of formula (I) are inhibitors of the enzyme 5-lipoxygenase and are thus useful as therapeutic agents for the treatment of allergic and inflammatory disease conditions.
摘要:
L'invention se rapporte à un procédé pour la séparation de gibbérellines contenues dans des mélanges gibbérelliques par silylation ou désilylation sélectives, ainsi qu'à des gibbérellines essentiellement pures ainsi préparées. Pour obtenir cette séparation, on ajoute par exemple de l'imidazole à un mélange de gibbérellines GA4 et GA7 dans du diméthylformamide (DMF). Après dissolution complète de l'imidazole, on ajoute du chlorure de butyldiméthylsilyle. Après avoir remué pendant 2 jours on ajoute de l'acide acétique qui précipite en un solide blanc (éther de silyle de GA7). Après filtrage, la gibbérelline GA4 est récupérée du filtrat. La désilylation de l'éther de silyle de GA7 produit la gibérelline GA7.
摘要:
In one aspect, the invention relates to a process for preparing 6-O-substituted erythromycin derivatives comprising reacting 2'-substituted and optionally 4'-substituted 9-oxime erythromycin derivatives with an alkylating agent in the presence of a palladium catalyst and phosphine. In another aspect, the invention relates to processes for preparing 6-O-substituted erythromycin ketolides using the palladium-catalyzed alkylation reaction.
摘要:
A process of preparing 6-O-alkylerythromycin A using 9-oximesilyl erythromycin A derivatives is provided. 9-Oximesilyl- and 6-O-alkylerythromycin A derivatives used in the preparation of 6-O-alkylerythromycin A are also provided.